Cost-effectiveness secondary analysis of the NOR-DRUM B trial (n=454) in immune-mediated inflammatory diseases on infliximab: proactive drug monitoring cost €592 less per patient over 1 year (95% CI -1304 to 107) with similar QALYs; 95% probability of cost-effectiveness.
Secondary analysisn = 454
Holly et al. Cost-effectiveness of proactive therapeutic drug monitoring of maintenance infliximab treatment in patients with immune-mediated inflammatory diseases: results from a randomised controlled trial